Close this panel
Browse By Date
Browse By Poster Author
Browse By Title
Close this panel



Mustafa Kinaan, MD – Endocrinology Fellow, University of Central Florida College of Medicine/HCA GME Consortium

Akin Eraslan, MD – Endocrinologist, Division of Endocrinology, Orlando VA Medical Center.

Hanford Yau, MD, FACP, FACE – Endocrinologist, The University of California, San Francisco, Fresno, CA

Kenneth Simon, DO – Oncologist, Division of Hematology and Oncology, Orlando VA Medical Center.


Objective : This case highlights the importance of testosterone level monitoring in prostate cancer patients after medical or surgical castration.

Methods : This is a case report. Please see details under discussion section.

Results :

This is a case report. Please see details under discussion section.

Discussion :

We present the case of a 73-year-old Caucasian male with history of adenocarcinoma of the prostate (pT2CN0M0 with Gleason score of 9) undergoing androgen deprivation therapy. The patient underwent radical prostatectomy upon initial diagnosis and was later started on androgen deprivation therapy following local recurrence of tumor with involvement of pelvic lymph nodes. Despite treatment with leuprolide, he continued to have total testosterone levels as high as 294.4 ng/dL as well as elevated prostate specific antigen (PSA).  During routine surveillance CT scan for cancer restaging, patient was found to have incidental bilateral adrenal nodular hyperplasia. He was referred to our endocrinology clinic for further evaluation of adrenal nodular hyperplasia and failure to suppress his testosterone levels. Given concerns about overproduction of adrenal androgens, the levels of androstenedione and dehydroepiandrosterone were obtained and both were elevated. Consequently, an adrenocorticotropic hormone (ACTH) stimulation test was performed demonstrating significant elevation in 17-hydroxyprogesterone at baseline (19,910 ng/dL) with increase to (>20,000 ng/dL) at 30 and 60 minutes. Cortisol level, however, remained unchanged at ~5 mcg/dL throughout the stimulation test.  Based on these results, genetic testing for congenital adrenal hyperplasia was pursued revealing a common and rare mutation of the CYP21A2 gene. The first mutation was located in intron 2 and is usually associated with simple virilizing or salt wasting phenotypes of classic congenital adrenal hyperplasia. The second common mutation detected was in the I172N sequence and is associated with the simple virilizing phenotype. The patient had no salt-wasting features and was clinically diagnosed with simple virilizing, classic congenital adrenal hyperplasia. The patient was started on dexamethasone and had marked decrease in his adrenal androgens, testosterone, and PSA levels. 21-hydroxylase deficiency comprises nearly 95% of all congenital adrenal hyperplasia cases with an incidence of 1 in 10,000 in Western countries. Males with the simple virilizing subtype are at risk of not being diagnosed because they are phenotypically normal at birth. 

Conclusion : Inadequate responses to androgen deprivation therapy should trigger further evaluation for congenital adrenal hyperplasia, a condition that is often overlooked.

Rate This Poster

Stuff for notes
Stuff for Message board

Share Poster


Technical Support

(877) 426-6323

[email protected]


SUBMIT FEEDBACKfeedback icon

We really appreciate your feedback on the eventScribe website. We use the data to improve the experience and simplify the process for users like you.


Log In / Sign Up

Already have an Event Scheduler or mobile app login? Login with those details. If not, create a login.

Log In   Sign Up
Access your bookmarked poster and notes by logging in ...   Sign up to take notes on poster, bookmark poster, and submit feedback.
  Lost your access key?      
You need to be logged in to bookmark posters, save notes, or rate posters.